Agilent Technologies Displays Cancer Research Innovations at AACR 2017
2 Apr 2017
Agilent Technologies Inc. has announced it will showcase some of its most recent technological advances in the areas of cell analysis and genomics at the AACR Annual Meeting 2017, being held April 1 - 5, 2017 in Washington, D.C.
Agilent will preview its newest next-generation sequencing (NGS) library prep solution – SureSelectXT HS – providing the first complete target enrichment solution, from quality control to target enrichment to analysis and interpretation, that is optimized for low-input formalin-fixed, paraffin-embedded (FFPE) samples. Additionally, SureSelect XT HS incorporates molecular barcodes, which improves precision and produces higher complexity libraries on a wide range of tissue types.
“With SureSelectXT HS, researchers will now be able to sequence deeper and achieve greater sensitivity, increasing confidence in their results,” said Rebecca Brandes, global marketing director for Cancer Genetics at Agilent Technologies. “Molecular barcodes increase variant calling accuracy, reduce false positive calls and improve data quality overall.”
Also on show at AACR will be the new Agilent Seahorse XF Glycolytic Rate Assay. This innovative assay is as accurate as a lactate assay, but provides more by reporting real time changes in both central cellular metabolic pathways, enabling the identification of how and when metabolic switches such as the Warburg effect occur. This ability to delineate the different energy pathways used by various tumors will help research scientists develop novel approaches to inhibit cancer cell survival and growth.
“Cancer cells can be dependent on pathways fueled by specific substrates for survival or proliferation, offering an opportunity to identify and confirm metabolic liabilities as therapeutic targets,” said David Ferrick, Ph.D., senior director of the Cell Analysis Division at Agilent Technologies. “The Agilent Seahorse XF assay platform enables the study of metabolic pathways and fuels that cancer cells depend on to generate energy.”
AACR 2017 will feature seminars and workshops conducted by leading scientists from around the world, including some Agilent customers. Visit Agilent Technologies at booth #2429 to learn more.
Related Products
Request Quote for All Products
SureSelect Focused Exome
Agilent TechnologiesThe SureSelect Focused Exome is a highly targeted design that enables analysis of only disease-associated targets, enabling superior coverage of disease-associated regions even on benchtop sequencers. This design provides 20 or more reads for 95% of targets at 1.5Gb (100x) of sequencing and 98% of targets with 3Gb (200x) of sequencing.
SureSelect Custom RNA
Agilent TechnologiesAgilent’s market leading SureSelect platform provides a complete portfolio of catalog and custom products, providing the flexibility you need from discovery to follow-up studies. Agilent’s custom solutions offer the only available method for target enrichment of RNA, allowing you to target your regions of interest using our free web portal SureDesign. Custom solutions are available for DNA and RNA target enrichment. • The only RNA target enrichment offering, enabling capture of 1kb to 24Mb and and more • Easy design process using intuitive SureDesign software or Agilent’s Design Service • Efficient workflows for post-capture (XT) pooling • Create SureSelect designs specific to your research needs using Agilent's SureDesign tool
Custom SureSelect
Agilent TechnologiesAgilent’s market leading SureSelect platform provides a complete portfolio of catalog and custom products, providing the flexibility you need from discovery to follow-up studies. Agilent’s custom solutions allow you to target your regions of interest using our free web portal SureDesign. Custom solutions are available for DNA and RNA target enrichment.